Story perspectives

Yeztugo Approved: HIV Activists Celebrate Insurance Breakthrough

1/29/2026

31 4

Summary

Story summary

HIV/AIDS activists celebrated the approval of Yeztugo, an injectable pre-exposure prophylaxis (PrEP) medication.
Insurers were initially reluctant to cover Yeztugo due to its $30,000 annual cost.
CVS Health reversed the decision and added Yeztugo to its formulary after negotiations with Gilead Sciences.
Medicaid and ACA marketplace plans provide coverage, while private insurers respond more slowly.
Over 85% of U.S. insurers have agreed to cover Yeztugo, but access may remain limited.

1 of 1

Story summary

HIV/AIDS activists celebrated the approval of Yeztugo, an injectable pre-exposure prophylaxis (PrEP) medication.
Insurers were initially reluctant to cover Yeztugo due to its $30,000 annual cost.
CVS Health reversed the decision and added Yeztugo to its formulary after negotiations with Gilead Sciences.
Medicaid and ACA marketplace plans provide coverage, while private insurers respond more slowly.
Over 85% of U.S. insurers have agreed to cover Yeztugo, but access may remain limited.